Statement: the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 13/50 (26.00%)   Febrile neutropenia 3/50 (6.00%)   Neutropenia 1/50 (2.00%)   Pancreatitis 1/50 (2.00%)   Cholangitis 1/50 (2.00%)   Cholelithiasis 1/50 (2.00%)   Anaphylactic reaction  [1]1/50 (2.00%)   Pneumonia 1/50 (2.00%)   Pneumonitis chemical 1/50 (2.00%)   Spinal compression fracture 1/50 (2.00%)   Dehydration 1/50 (2.00%)   Electrolyte imbalance 1/50 (2.00%)
Secondary_evidence: Adverse Events 1:   Total: 1/3 (33.33%)   FEBRILE NEUTROPENIA 0/3 (0.00%)   LYMPH NODE PAIN 0/3 (0.00%)   NEUTROPHIL COUNT DECREASED 0/3 (0.00%)   THROMBOCYTOPENIA 0/3 (0.00%)   CHEST PAIN 0/3 (0.00%)   DEHYDRATION 0/3 (0.00%)   PLEURAL EFFUSION 1/3 (33.33%)   PNEUMONITIS 0/3 (0.00%)   PULMONARY INFILTERATES 0/3 (0.00%)   ALOPECIA 0/3 (0.00%)